A Comparison of Two Devices for Taking Measurements of the Eye to Assist in Lens Selection for Cataract Surgery

Sponsor
Ziemer Ophthalmic Systems AG (Industry)
Overall Status
Completed
CT.gov ID
NCT03396003
Collaborator
(none)
112
1
2
6.8
16.4

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the Ziemer Ophthalmic Systems AG GALILEI G6 Lens Professional to the Oculus Pentacam® AXL for taking images and measurements of the anterior segment of the eye, including the cornea, pupil, anterior chamber and lens, to assist in determining the power of the intraocular lens for implantation.

Condition or Disease Intervention/Treatment Phase
  • Device: GALILEI G6 Lens Professional
  • Device: Oculus Pentacam AXL
N/A

Detailed Description

A corneal topographer/biometer named GALILEI G6 Lens Professional was developed by Ziemer Ophthalmic Systems AG for the measurement of anterior segment geometry and axial intraocular distances. The measurement principle of the corneal topographer corresponds to that of the commercially available Galilei G4 Dual Scheimpflug Analyzer, whereas the measurement principle of the biometer is based on low coherence interferometry/reflectometry, which has been widely used and applied clinically by a number of predicate devices.

One complete measurement consists of a corneal topography/ tomography scan followed by three consecutive, axial biometry scans of the anterior segment (cornea and crystalline lens) and three consecutive, axial biometry scans of the retina. The measurement process is continuous but divided into three alignment-click-steps.

Such measurements can be applied to given Intra Ocular Lens (IOL) types and IOL equations, to permit the calculation of recommended IOLs to be implanted during cataract surgery in order to achieve the desired vision correction.

The primary objectives of this clinical study are to: 1) evaluate the inter-device repeatability, inter-operator repeatability and reproducibility of the GALILEI G6 Lens Professional in repeated measurements of anterior segment geometry and axial intraocular distances and, 2) demonstrate substantial equivalence through examining agreement of the GALILEI measurements to those of the predicate device, the Pentacam® AXL.

Study Design

Study Type:
Interventional
Actual Enrollment :
112 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
GALILEI G6 Lens Professional vs. a Predicate Device: a Comparison Study
Actual Study Start Date :
Jan 5, 2018
Actual Primary Completion Date :
Aug 1, 2018
Actual Study Completion Date :
Aug 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: GALILEI G6 Lens Professional

The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.

Device: GALILEI G6 Lens Professional
Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators

Active Comparator: Oculus Pentacam AXL

The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.

Device: Oculus Pentacam AXL
A single measurement of the eye will be taken using the Oculus Pentacam AXL

Outcome Measures

Primary Outcome Measures

  1. Axial Length (AL) Measurement in millimeters (mm) [One day]

    Repeatability and reproducability across and between evaluations

  2. Central Corneal Thickness (CCT) Measurement in micrometers (µm) [One day]

    Repeatability and reproducability across and between evaluations

  3. Radius Flat Meridian (R flat) Measurement in millimeters (mm) [One day]

    Repeatability and reproducability across and between evaluations

  4. Radius Steep Meridian (R steep) Measurement in millimeters (mm) [One day]

    Repeatability and reproducability across and between evaluations

  5. Mean Radius (Rm) Measurement in millimeters (mm) [One day]

    Repeatability and reproducability across and between evaluations

  6. Corneal Cylinder Measurement in diopters (D) [One day]

    Repeatability and reproducability across and between evaluations

  7. Corneal Cylinder Axis (A flat) Measurement in degrees [One day]

    Repeatability and reproducability across and between evaluations

  8. Anterior Chamber Depth (ACD) Measurement in millimeters (mm) [One day]

    Repeatability and reproducability across and between evaluations

  9. Horizontal White-to-White distance (WtW) Measurement in millimeters (mm). [One day]

    Repeatability and reproducability across and between evaluations

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Satisfies one of the subject group categories and the enrollment quota for that category has not been reached:
  1. Normal eyes (phakic eyes without cataracts or corneal disease, refraction ≥ -5.5 D or ≤ +5.0 D)

  2. Eyes having undergone previous refractive surgery (LASIK or PRK)

  3. Eyes with cataracts (LOCS III grading with grades 2-6 in any or all of the posterior subcapsular (P2-P5), nuclear (N2-N5) and cortical (C2-C5), assessed by slit lamp examination; no other known ocular pathology)

  4. Eyes with severe myopia (≤ -6 D according to the American Academy of Ophthalmology)

  5. Eyes with severe hyperopia (≥ +5.25 D according to the American Academy of Ophthalmology)

  6. Eyes with previous cross-linking and eyes with advanced keratoconus

  • Manifest refraction sSpherical eEquivalent Refraction (MRSER) between -10dpt and +10dpt as measured by cycloplegic autorefraction assessed less than 12 months prior to enrollment

  • Best corrected visual acuity (BCVA) of LogMAR 0.2 or better

Exclusion Criteria:
  • Strabismus, nystagmus, amblyopia, anisometropia (difference in MRSER>3D)

  • Angle closure glaucoma

  • Seizure disorder, brain damage, Down Syndrome, Trisomy 13 or 18, Cerebral Palsy or other serious ophthalmic or central nervous system disorders

  • Severe dry eye

  • Severe corneal scarring

  • Inability to hold gaze

  • Inability to see fixation target

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ziemer Ophthalmic Systems AG Port Switzerland

Sponsors and Collaborators

  • Ziemer Ophthalmic Systems AG

Investigators

  • Principal Investigator: Majid Moshirfar, MD,

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ziemer Ophthalmic Systems AG
ClinicalTrials.gov Identifier:
NCT03396003
Other Study ID Numbers:
  • ZIEMER_G6
First Posted:
Jan 10, 2018
Last Update Posted:
Sep 26, 2018
Last Verified:
Sep 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 26, 2018